Compare FHI & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHI | MMED |
|---|---|---|
| Founded | 1955 | 1983 |
| Country | United States | United States |
| Employees | N/A | 2800 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.3B |
| IPO Year | 1998 | 2026 |
| Metric | FHI | MMED |
|---|---|---|
| Price | $57.88 | $16.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $54.20 | $22.56 |
| AVG Volume (30 Days) | 543.9K | ★ 1.0M |
| Earning Date | 04-30-2026 | 06-03-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $1,102,924,000.00 | N/A |
| Revenue This Year | $9.90 | $15.99 |
| Revenue Next Year | $4.35 | $10.00 |
| P/E Ratio | $45.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $46.66 | $10.65 |
| 52 Week High | $60.77 | $17.86 |
| Indicator | FHI | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 64.99 |
| Support Level | $54.24 | $14.70 |
| Resistance Level | $60.00 | N/A |
| Average True Range (ATR) | 1.22 | 0.87 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 60.35 | 81.85 |
Federated Hermes provides asset management services for institutional and individual investors. The firm had $907.1 billion in managed assets at the end of the first quarter of 2026, composed of equity (11%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (75%) funds. The company's cash management operations are expected to generate around 53% of Federated's revenue this year, compared with 30%, 10%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.